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Abstract: 
RATIONALE: Procollagen III amino-terminal propeptide (P-III-NP) is 
monitored using immunoassays as a biomarker for growth hormone 
administration in human doping control and in clinical diagnostics. These 
immunoassays have known drawbacks and research is ongoing to develop 
a mass spectrometric (MS) method. A lack of traceable reference material, 
presence of post translational modifications (PTMs), and small blood 
concentration complicate the development of targeted analytical methods 
for P-III-NP quantification.  
METHODS: Tryptic digest products of P-III-NP were assessed by liquid 
chromatography-MS (LC/MS). In silico digestion was used to predict P-III-
NP peptides for MS analysis; however these excluded PTMs. With a priori 
knowledge of PTMs, we associated experimental P-III-NP peptides with 
those derived by in silico digestion. Synthesized P-III-NP peptides, hT1 
(human) and T5 (human/bovine), were used to develop sensitive micro- 
and nano-flow LC/MS methods to analyse P-III-NP, originating from human 
serum, semi-quantitatively.  
RESULTS: P-III-NP peptides, T1 and T5, were identified using high 
resolution accurate MS (HRAMS). PTMs modified the mass of observed 
peptides. N-terminal pyroglutamation (pE) in T1 and several hydroxylated 
prolines (hP) in T5 (G-X-hP motif) were observed. With PTM, hT1 and T5 
were observed in a digest of immuno-captured P III NP by LC/MS. Using a 
semi quantitative approach, hP-III-NP at a basal concentration of 2 ng/mL 
(50 pmol) could be estimated from a 200 µL sample volume.  
CONCLUSIONS: Consideration of PTMs is needed to identify P-III-NP 
peptides produced by digestion with trypsin. The information presented 
here now gives the most appropriate peptide sequences for synthesizing 
suitable reference material required for quantification of human P-III-NP in 
blood and evidences methodology that is sufficiently sensitive to develop a 
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quantitative method.  
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Peptide Selection for the Quantification of P-III-NP in Human Serum by Mass 1 
Spectrometry 2 
Danielle Moncrieffe, Mark C. Parkin, David Cowan* 3 
Drug Control Centre, King’s Forensics, Department of Analytical, Environmental and 4 
Forensic Sciences, King’s College London, London, UK. 5 
RATIONALE: Procollagen III amino-terminal propeptide (P-III-NP) is currently monitored 6 
in human doping control as a biomarker for growth hormone administration and also in 7 
clinical diagnostics using immunoassays. Drawbacks to this approach have been highlighted, 8 
and research is ongoing to develop a mass spectrometric (MS) method to complement these 9 
methods. However, a lack of traceable reference material, presence of post translational 10 
modifications (PTMs), and small blood concentration implicate the development of targeted 11 
analytical methods for P-III-NP quantification. 12 
METHODS: Tryptic digest products of P-III-NP were assessed by liquid chromatography-13 
MS (LC/MS). In silico digestion was used to predict P-III-NP peptides for MS analysis; 14 
however these excluded PTMs. With a priori knowledge of PTMs, we associated 15 
experimental P-III-NP peptides with those derived by in silico digestion. Synthesized 16 
P-III-NP peptides, hT1 (human) and T5 (human/bovine), were used to develop sensitive 17 
micro- and nano-flow LC MS methods to analyse P-III-NP, originating from human serum, 18 
semi-quantitatively. 19 
RESULTS: P-III-NP peptides, T1 and T5, were identified using high resolution accurate MS 20 
(HRAMS). PTMs modified the mass of observed peptides. N-terminal pyroglutamation (pE) 21 
in T1 and several hydroxylated prolines (hP) in T5 (G-X-hP motif) were observed. With 22 
PTM, hT1 and T5, were observed in a digest of immuno-captured P-III-NP by LC/MS. Using 23 
a semi-quantitative approach, hP-III-NP at basal concentrations of 2 ng/mL (50 pmol) could 24 
be estimated from a 200 µL sample volume. 25 
CONCLUSIONS: Consideration of PTMs is needed to identify P-III-NP peptides produced 26 
by digestion with trypsin. The information presented here now gives the most appropriate 27 
peptide sequences for synthesizing suitable reference material required for quantification of 28 
human P-III-NP in blood and evidences methodology that is sufficiently sensitive to develop 29 
a quantitative method. 30 
Keywords: procollagen III amino-terminal propeptide; post-translational modification; in 31 
silico digestion; tryptic digest; doping control 32 
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Introduction 35 
Type III collagen is the second most abundant collagen (varying in abundance with age) in 36 
humans; it is typically found with type I collagen and is present in tissues with elastic 37 
properties such as skin, blood vessels and various internal organs[1]. Type III collagen is 38 
formed from a precursor pro-collagen unit in the cell, which includes amino- and carboxyl-39 
terminal extension propeptides (denoted P-III-NP and P-III-CP, respectively) [1, 2]. 40 
P-III-NP is a clinical biomarker used to monitor chronic active hepatitis, liver fibrosis and 41 
cirrhosis [3-6]. Elevated levels of P-III-NP have been associated with hormonally induced 42 
growth [2, 7], making P-III-NP one of two biomarkers used to detect rhGH (recombinant 43 
human growth hormone) doping in sport [8]; the other being insulin-like growth factor I 44 
(IGF-I). These compounds have little diurnal variation and are largely unaffected by exercise 45 
or sex, but respond to hGH administration. Also, body mass index and race contribute little to 46 
the variability of these markers [8]. For humans, blood P-III-NP levels are inversely 47 
proportional to age, with maximum levels observed during pubertal years. Sex however 48 
affects P-III-NP blood concentrations, men (average conc. 5.4 ±2.3 ng/mL) having a slightly 49 
bigger natural concentration than women (average conc.5.1 ±1.5 ng/mL)[9]. 50 
P-III-NP consists of three identical 130 amino acid pro α1- chains, connected by disulphide 51 
cysteine bonds to create a unique pro-collagen subunit with three distinct domains, Col 1-3 [1, 52 
10]. The first domain, Col 1, has a globular structure resulting from its richness in acidic 53 
amino acids and cysteine. There are five intra-molecular disulphide bonds within each 54 
pro α1-chain forming this domain, causing it to fold into several loops to expose more 55 
hydrophilic amino acids increasing interaction with water [10-12]. The second domain, Col 3, is 56 
triple helical, consisting of the tri-peptide repeat G-X-Y, with X and Y most often being a 57 
proline residue. The high proline and glycine (G) content within this region results in a left-58 
handed super-helical twist of the three pro α1 chains to form a “collagen-like” conformation. 59 
The six inter-molecular disulphide cysteine bonds in the telopeptide domain, Col 2, which 60 
can be found at the C-terminus of the peptide, ensure that the three chains are close together 61 
facilitating the twisted conformation[10, 11]. 62 
In doping control, measurements of P-III-NP have relied on the use of radioactive 63 
immunoassays (RIA), RIA-gnost® (CisBio Bioassays) and UniQ® P-III-NP RIA (Orion 64 
Diagnostica) and the non-radioactive Advia Centaur® immunoassay platform (Siemens 65 
Healthcare Diagnostics Inc.) [1, 13]. In the absence of international reference material for 66 
human P-III-NP, these immunoassays use bovine P-III-NP (97 % sequence homology with 67 
human) as reference; thus, relying on the cross- reactivity of epitopes for human and bovine 68 
material. More recently an enzyme linked immunosorbent assay (ELISA) (CisBio Bioassays) 69 
has been developed; however, it is still to be evaluated by anti-doping laboratories. 70 
World Anti-doping Agency (WADA), the body that accredits laboratories to undertake 71 
human anti-doping analysis, stipulates that confirmation of elevated P-III-NP requires the use 72 
of two independent immunoassays recognising different epitopes (see WADA International 73 
Standard for Laboratories version 9.0, 2016 paragraph 5.2.4.3.1.3). This makes laboratories 74 
reliant on the use of RIAs, needing licensing for handling radioactive material. Apart from 75 
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the difficulties related to handling radioisotopes, other limitations are associated with these 76 
RIAs including their lack of selectivity for the human homologue, lack of harmonisation of 77 
units of measurement and epitopes used between methods, and possible change or withdrawal 78 
of assays by their manufacturers, as has occurred previously [14, 15].Furthermore, the decision 79 
limits distinguishing negative and positive results is method specific and need modification 80 
whenever an assay is changed. The second biomarker used to evidence human growth 81 
hormone administration is IGF-I, a 7.5 kDa protein with circulating concentrations typically 82 
in excess of 100 ng/mL [15]. With the acceptance by WADA of a validated mass spectrometry 83 
(MS) method for this protein, there is now more standardisation of IGF-I measurement. Thus, 84 
to overcome the limitations described, a MS method for the analysis of P-III-NP seems 85 
timely to complement or replace the already existing RIAs. 86 
Absence of a traceable international reference material for human P-III-NP (hP-III-NP) 87 
makes the development of specific methods reliant on endogenous sources. The small serum 88 
concentration (25-125 pM) and medium protein size of P-III-NP (~42 kDa) [15], make it 89 
difficult to obtain adequate MS sensitivity from intact protein analysis and thus a digest 90 
approach seems appropriate. Digestion of proteins with the endoprotease trypsin usually yield 91 
peptide fragments for MS analysis with favourable ionisation properties [16]. Unique digestion 92 
peptide fragments of P-III-NP obtained from in silico digestion were searched against protein 93 
databases and selected for MS analysis. Although post-translational modifications (PTMs) of 94 
proteins are not uncommon, for P-III-NP, modifications are not present in the in silico 95 
generated reference peptide sequences. Based on the structure and amino acid composition of 96 
P-III-NP, PTMs can be predicted, but require confirmation; these affect the observed mass to 97 
charge ratio (m/z) of the ions obtained from the peptides selected from in silico digestion. 98 
PTMs across P-III-NP include pyroglutamation in Col 1 [11], hydroxylation of proline 99 
residues in the “collagen-like” Col 3 domain, de-amidation of susceptible asparagine residues 100 
across the protein, and possible N-linked glycosylation in Col 2 [11, 17]. 101 
Here we confirm the presence, in human serum, of the selected in silico P-III-NP peptides 102 
and their PTMs, for the first time. Trypsin digested bovine P-III-NP (bP-III-NP) was 103 
analysed by high-resolution accurate mass spectrometry (HRAMS) to identify peptides. Once 104 
identified, pure human variants of these peptides were synthesized and used to develop 105 
sensitive nano- and micro-flow liquid chromatography mass spectrometry (LC/MS) methods 106 
capable of identifying trypsin digested endogenous hP-III-NP separated from a pooled serum 107 
sample. This work highlights suitable tryptic peptides to enable the development of reliable 108 
quantification methods, once the necessary standardised reference material (native and heavy 109 
labelled) for these proteins or intact P-III-NP are available. 110 
Materials and methods 111 
All water used was purified using an Elga Purelab® flex water purification unit and had 112 
~18 MΩ.cm resistivity. Sequencing grade modified trypsin (porcine) was purchased from 113 
Promega (Wisconsin, USA). Dithiothreitol (DTT), electrophoresis purity reagent, was 114 
purchased from Bio-Rad Laboratories (Hertfordshire, UK). Iodoacetamide (IDA, ≥99 %, 115 
HPLC), ammonium bicarbonate (≥99 %, Reagent Plus®), trifluoroacetic acid (99 %, Reagent 116 
Plus®), tetracosactide (adrenocorticotropic hormone fragment 1-24 (human, rat) ≥97 %) and 117 
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albumin solution human (HSA, 30 % in 0.85 % sodium chloride, protease free), were 118 
purchased from Sigma Aldrich (St. Louis, MO, USA). Analar NormaPur formic acid (99-119 
100 %) was purchased from VWR Chemicals (Fontenay-sous-Bois, France). Acetonitrile 120 
(HPLC grade) and acetic acid glacial (Analytical Reagent grade) were purchased from Fisher 121 
Scientific (Loughborough, UK). 122 
In silico digestion 123 
Reference sequences for human (UniProt accession no. P02461(24-153)) and bovine 124 
(UniProt accession no.Q08E14 (24-153)) P-III-NP were accessed from UniProtKB 125 
(http://www.uniprot.org/uniprot/P02461, last accessed September 12, 2017) [18]. Theoretical 126 
digestion of these proteins with trypsin (no missed cleavage allowed) was done using the 127 
ExPasy-Peptide Cutter [19] and USCF Protein Prospector [20]. Digest products were assessed 128 
within UniProtKB using the basic local alignment tool (BLAST, 129 
http://www.uniprot.org/blast/, last accessed September 12 2017) to identify the uniqueness of 130 
the peptide fragments to P-III-NP. 131 
Bovine P-III-NP sample 132 
A bP-III-NP sample (~10 µg/mL, unspecified purity) in human serum albumin (HSA, 0.1 %) 133 
was kindly donated by the Institute of Bioanalytics, L.L.C (Branford, USA). This was 134 
assessed using UniQ® P-III-NP RIA (Orion Diagnostica, Espoo, Finland) to obtain an 135 
approximate concentration. HSA (0.1 %) in phosphate buffered saline (PBS, 0.01 M) both 136 
purchased from Sigma Aldrich (St. Louis, MO, USA) was used as negative control. 137 
Trypsin digestion and LC/HRAMS analysis of bovine P-III-NP 138 
P-III-NP and negative control (0.1 % HSA in 0.01 M phosphate buffered saline) samples 139 
were treated as follows. Each sample (100 µL) was evaporated to dryness and reconstituted in 140 
ammonium bicarbonate (50 µL, 100 mM) in a LoBind Eppendorf® tube (Sigma Aldrich, 141 
Hamburg, Germany). DTT in 100 mM ammonium bicarbonate (5 µL, 100 mM) was added to 142 
the samples, which were incubated at 60 °C with mixing in an Eppendorf Thermomixer® at 143 
900 rpm for 10 min. Samples were left to incubate at 60 °C for a further 50 min without 144 
mixing. After cooling, freshly prepared IDA in 100 mM ammonium bicarbonate (5 µL, 145 
250 mM) was added to the samples and vortexed before leaving in the dark for 30 min. 146 
Sequencing grade modified trypsin (4 µg) was added to the samples, which were incubated at 147 
37 °C overnight with mixing at 1400 rpm. To stop trypsin activity, formic acid (10 µL, 2 %) 148 
was added to each sample before evaporating to dryness and reconstituting in mobile phase 149 
(50 µL, 0.3 % formic acid, 5 % acetonitrile in water). Samples were then transferred to a 150 
suitable autosampler vial and analysed by LC/HRAMS. 151 
Using a Thermo Fisher™ Dionex™ UltiMate™ 3000 UHPLC (Ultra High Performance 152 
Liquid Chromatography) system (Waltham, MA, USA), gradient separation of each sample 153 
(10 µL) was achieved on a Waters Acquity® Ultra Performance LC BEH C18 column (130Å, 154 
1.7 µm, 2.1 x 50 mm. Milford, MA, USA) with mobile phase A, 0.3 % formic acid in water, 155 
and B, 0.3 % formic acid in acetonitrile. Using a flow rate of 0.3 mL/min, mobile phase B 156 
was held at 5 % for 3 min, then increased to 90 % for 5 min before returning to 5 % for a 2 157 
min column re-equilibration. MS data was acquired using a Thermo Fisher™ Q-Exactive™ 158 
HRAMS system with HESI II (heated ESI) ion source operating in positive mode at a 159 
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resolving power of 140,000 FWHM. Three separate experiments were conducted in positive 160 
ionisation mode: a full scan HRAMS, a targeted tandem mass spectrometry-high resolution 161 
mass spectrometry (MS/HRAMS), and a data dependent MS/HRAMS. 162 
The ESI sheath and auxiliary nitrogen gas flows were set to 70 and 13 arbitrary units 163 
respectively, the sweep gas was set to zero. The capillary and heater temperature was 300 ⁰C 164 
and 325 ⁰C respectively. The spray voltage was 3.75 kV. Nitrogen was used as the source and 165 
collision gas. For full scan HRAMS experiments, an AGC target of 1 x 106 was used with a 166 
maximum injection time of 100 ms. Appropriate scan ranges were selected for initial 167 
HRAMS experiments to observe precursor ions with single, double or triple charges. 168 
MSHRAMS analyses were run using appropriate m/z values for the precursor ion (±1 u) 169 
where necessary. Top 10 and targeted data dependent analysis was performed for the T1 170 
doubly charged ion, with an AGC target of 1.5 x 104. 171 
LC/HRAMS data was reviewed on Thermo Scientific™ Xcalibur™ 2.2 SP 1.48 Qual 172 
Browser software; extracted ion chromatograms were produced with a tolerance of ±5 ppm. 173 
Data-dependent results were checked against the Matrix Science Mascot server (version 174 
2.2.06) searching against all taxonomic entries in the UniProtKB_sprot_130200. Allowing 175 
for a peptide tolerance of 5 ppm with 3 missed cleavages, with carbamidomethylation as a 176 
fixed modification oxidation of proline, N-terminal pyroglutamation and asparagine 177 
deamidation as variable modifications. 178 
Trypsin derived P-III-NP peptides 179 
Authentic PTM hP-III-NP peptides, hT1 (Q-NH3QEAVDGGCSHLGQSYADR) and 180 
T5 (GDP-OHGPP-OHGIP-OHGR) were both synthesized and purchased from Thermo Fisher 181 
(Life Technologies limited, Paisley, UK). 182 
Reduction of disulphide bridges in hT1 (100 µL, 1 µg/mL in 100 mM ammonium 183 
bicarbonate) was achieved by adding DTT in 100 mM ammonium bicarbonate (5 µL, 184 
100mM) and incubating at 60 ˚C with mixing at 900 rpm for 10 min then, without mixing, for 185 
an additional 50 min. Disulphide sites were blocked by alkylating with IDA in 100 mM 186 
ammonium bicarbonate (5 µL, 250 mM) at room temperature for 30 min. 187 
Pure peptide standards for hT1 (reduced and alkylated) and T5 were prepared in mobile phase 188 
(50 µL, 0.3 % formic acid, 5 % acetonitrile in water) at approximate concentrations: 5 pM, 189 
10 pM, 20 pM, 50 pM, 100 pM, 200 pM, 500 pM and 1 nM. Standards were analysed by 190 
micro- and nano-flow LC/MS to establish an approximate limit of detection (LOD); where 191 
the signal to noise is greater than 3:1 for all diagnostic ions. 192 
Nano- and micro-LC/MS methods 193 
Micro-flow and nano-flow LC/MS were performed on a Waters nanoAcquity® Ultra 194 
Performance LC® coupled to a Waters Xevo™ TQ-S MS in positive MS mode. For micro-195 
flow, the mass spectrometer was interfaced with a Waters narrow gauge ESI needle (60 µm 196 
I.D.) on a conventional ion source. A low dead volume fused silica capillary (25 µm I.D) was 197 
used from the outlet of the column to the inlet of the ESI needle. The capillary voltage set to 198 
2.22 kV and the cone voltage was set to 22 V with an offset of 27 V. The source and 199 
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desolvation temperature were 150 ˚C and 350 ˚C, respectively. The cone and desolvation gas 200 
flow were 145 and 450 L/h. Collision (argon) and nebuliser (nitrogen) gas flow was 0.17 201 
mL/min and 7 bar, respectively. An MS mode collision energy of 4 eV was applied. For 202 
nano-flow, the mass spectrometer was interfaced with a nano-ESI emitter (30 µm I.D. New 203 
Objective, Woburn, MA, USA) using a Waters nano-ESI Z-Spray source (Waters, USA), 204 
with the capillary voltage set to 1.75 kV. The cone voltage was set to 45 V with an offset of 205 
30 V. The source temperature was set to 83 ˚C, with a collision gas flow of 0.15 mL/min and 206 
a nebuliser gas flow of 7 bar. MS mode collision energy of 10 eV was applied. 207 
Micro-flow LC gradient separation of each sample (1 µL) was achieved on an Acquity® 208 
M-Class BEH 130 Å (C18, 1.7 µm, 300 µm x 150 mm) column at 45 ˚C with mobile phase 209 
A, 0.3 % formic acid in water, and B, 0.3 % formic acid in acetonitrile and a flow rate of 210 
8 µL/min. Mobile phase B was increased from 5 % to 60 % over 20 min, this was then 211 
increased to 90 % in 1.5 min and held for 30 sec, after which it was immediately returned to 212 
5 % and held for 3 min to re-equilibrate the column. 213 
For nano-flow LC, mobile phase A, 0.3 % formic acid in water, and B, 0.3 % formic acid in 214 
acetonitrile was used. Samples (5 µL) were trapped on an Acquity® UPLC® Symmetry C18 215 
nanoAcquity® 10K 2GV/M trapping column (100 Å, 5 µm, 180 µm x 20 mm) for 5 min at 216 
flow 10 µL/min with 1 % mobile phase B. The trapped analytes were then loaded onto an 217 
Acquity® UPLC® M-Class Peptide BEH C18 column (130 Å, 17 µm, 75 µm x 150 mm) at 218 
45 ˚C for separation by gradient elution. With a flow of 0.4 µL/min, mobile phase B was held 219 
at 5 % for 5 min, then increased to 9 % for 25 min and then 95 % for 2 min, before returning 220 
to 5 % and held for 8 min to re-equilibrate the column. 221 
Selected reaction monitoring for T1 and T5 were acquired for the transitions shown in Table 222 
1. LC/MS data was analysed using MassLynx Software version 4.1 (Waters, Milford, MA, 223 
USA). 224 
Extraction of P-III-NP from human serum for LC/MS 225 
Pooled human serum (100 µL) and HSA control (100 µL, 50 mg/mL) samples were brought 226 
to room temperature, before placing into a P3NP ELISA (CisBio Bioassays, Gif-sur-Yvette, 227 
France) microtitre plate containing immobilised anti-P-III-NP mouse monoclonal antibody. 228 
Samples were incubated overnight at 4 ˚C with shaking at 700 rpm. Liquid was then dispelled 229 
from the wells, which were then washed three times with PBS containing 0.3 % Tween® 20 230 
(300 µL). Bound P-III-NP was removed from the wells by incubating with 15 mg/mL 231 
tetracosactide, 33 % acetonitrile, 0.4 % TFA solution (100 µL) at 60 ˚C for 5 min while 232 
shaking at 900 rpm. The samples were then transferred to LoBind Eppendorf® tubes and 233 
digested with trypsin, before analysing by micro- and nano-flow LC/MS. Samples were 234 
compared to a T5 standard (100 pM) to determine their concentrations semi-quantitatively. 235 
Results and Discussion 236 
Theoretical digestion of P-III-NP with trypsin gave four unique in silico-derived peptides, T1, 237 
T2-4, T5 and T6, shown in Table 2. Of these peptides, T2-4, contains two tryptic no cleavage 238 
sites, at 21V-W-K-P-E and 81P-T-R-P-P, making this peptide uncharacteristically long for 239 
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trypsin and not ideal for mass spectrometry. As such it is not considered as a surrogate 240 
peptide for P-III-NP LC/MS methods. 241 
The activity of the bP-III-NP sample (~10 µg/mL) was assessed by immunoassay 242 
(2.7 µg/mL, 64.2 nM) using the UniQ® P-III-NP RIA, however the purity of the sample 243 
remains unknown. Data dependent analysis of peptide products obtained from trypsin 244 
digestion of this sample returned no hits for P-III-NP against the SwissProt database. This 245 
can be explained by the observation of PTMs affecting the observed mass of the in silico-246 
derived peptides (not reflected in the database) discovered during the visual analysis of 247 
LC/HRAMS data using extracted ion chromatograms produced by Xcalibur. 248 
Although helpful in identifying possible cleavage sites and presenting peptide fragments for 249 
MS analysis, the exclusion of PTM predictions in these search algorithms produced 250 
incomplete peptides for P-III-NP. Sole dependence on data obtained from these databases 251 
potentially prevents the identification of endogenous tryptic peptides without a priori 252 
knowledge of PTMs. 253 
Identification of P-III-NP peptides from trypsin digested bovine material 254 
Manual analysis of data obtained by LC/HRAMS on trypsin digested products of bP-III-NP, 255 
revealed a peptide eluting at 5.34 min with ions possessing a double charge at m/z at 256 
1030.9400 (±5 ppm) and a triple charge at m/z 687.6291 (±5 ppm). A product ion scan 257 
spectrum for this peptide was generated from the doubly-charged ion, which when sequenced 258 
corresponds with the amino acid sequence Q-NH3QEAVDGGCSHLGQSYADR. T1 originates 259 
from the Col 1 domain of P-III-NP, which is at the N-terminus of the protein. Post-260 
translational cyclization of amino-terminal Q in proteins and peptides is achieved by de-261 
amidation (loss of NH3) to form a pyroglutamate (pE) residue, as is the case for P-III-NP. The 262 
absence of unmodified bT1 within the experimental trypsin peptide products suggests that 263 
circulating P-III-NP is completely deamidated at the N-terminal Q. This is not surprising as 264 
N-terminal pyroglutamation is mostly spontaneous, however, it is can also be catalysed by 265 
glutaminyl cyclase, an enzyme found in both plants and animals [21]. Cyclization of this 266 
N-terminus Q, protects P-III-NP from exopeptidase degradation and makes the protein more 267 
hydrophilic. 268 
Another peptide eluting at 4.23 min, with ions possessing a single charge at m/z 1067.5116 269 
(±5 ppm), double charge at m/z 534.2594 (±5 ppm) and triple charge at m/z 356.5087 270 
(±5 ppm), was observed. A product ion scan spectrum was generated from the doubly-271 
charged ion, which when sequenced corresponded to the amino acid sequence 272 
GDP+OHGPP+OHGPGIP+OHGPGR. The addition of a hydroxyl group to proline in the Y 273 
position of the G-X-Y repeat is typical of collagen, where hydroxyproline residues at this site 274 
facilitate covalent hydrogen bonds to support the α-helical topology of this region. T5 275 
originates from the Col 3 domain and so it is not surprising that hydroxyprolines are observed 276 
in this peptide. 277 
No peptide corresponding to T6 was observed by LC/HRAMS, however, a potential 278 
N-glycosylation site is present at 127N-Y-S-P. The attachment of a complex oligosaccharide 279 
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to P-III-NP has been previously observed [17], with the most likely site of attachment being 280 
N-127. Without prior removal or characterisation of this possible carbohydrate unit, if 281 
glycosylated, the mass of T6 generated by trypsin digestion of bovine P-III-NP is unknown. 282 
To overcome this, the carbohydrate moiety can be cleaved from the protein prior to digestion, 283 
however this step increases sample handling, may cause loss of yield and complicates sample 284 
preparation. Further scrutiny of the T6 peptide reveals a susceptible post-digest spontaneous 285 
asparagine de-amidation site at the N-terminal N-97. The non-enzymatic nature of this de-286 
amidation leads to variability in the occurrence of this PTM [22], which affects the 287 
reproducibility of peptide generation in situ. Hence, T6 is not considered further as a potential 288 
surrogate for P-III-NP analysis. 289 
Figure 1: Extracted ion chromatogram at m/z 1030.9400 ±5 ppm and corresponding product 290 
ion scan spectrum of the fragmented carbamidomethylated PTM bT1 triply-charged peptide 291 
(±1 u) using a normalised collision energy of 30 %. The most abundant b- and y-ions are 292 
annotated, where no charge is indicated the peptide is singly-charged. 293 
Figure 2: Extracted ion chromatogram at m/z 534.2594 ±5 ppm and corresponding product 294 
ion scan spectrum of the fragmented PTM T5 doubly-charged peptide (±1 u) using a 295 
normalised collision energy of 20 %. The most abundant b- and y-ions are annotated, where 296 
no charge is indicated the peptide is singly-charged. 297 
Peptide selection 298 
Unique P-III-NP tryptic peptide T1 and T5 were fully characterised by MS-HRAMS analysis, 299 
with full coverage of the amino acid sequence through the identification of combined b- and 300 
y-ions produced by fragmentation. Confirmation of PTMs to the in silico sequence and the 301 
specificity of location is proven. Previous work with P-III-NP removed the pyroglutamate to 302 
facilitate Edman sequencing [11], data presented here shows evidence of the pyroglutamate 303 
replacing glutamine at the N-terminus of P-III-NP. For the T5 fragment, complete 304 
hydroxylation of proline in the Y position of the G-X-Y tri-peptide is shown; detailed 305 
analysis of full scan HRAMS data confirms the site specificity of this PTM, as no hP was 306 
observed for P in the X position. 307 
Although P-III-NP characterisation was done with bP-III-NP, the in silico derived T5 peptide 308 
sequence for human is the same; hence the PTMs associated with this peptide should be 309 
conserved in humans. For the T1 peptide, hT1 has an aspartic acid residue at position 6 which 310 
is replaced by glutamic acid (E) in bT1, resulting in a decrease in molar mass of 15.023 Da. 311 
This mass shift facilitates the possible differentiation of species by MS. From previous 312 
experiments, we have observed deamidation of the N-terminus Q to pE in pure in 313 
silico-derived T1 peptide (QQEAVEGGCSHLGQSYADR), thus supporting the theory of 314 
spontaneous pyroglutamation. The cause of pyroglutamation of the P-III-NP in our bovine 315 
sample is unknown. Due to the inherent instability of the unmodified peptide, we suggest that 316 
synthesized T1 peptides should be produced with an N-terminus pyroglutamate. 317 
Micro- and nano-flow LC/MS methods developed for PTM hT1 318 
(pEQEAVDGGCSHLGQSYADR) had LODs of 100 pM (100 amoles) and 5 pM 319 
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(25 amoles), respectively, whilst for T5 (GD(hP)GP(hP)GI(hP)GR) LODs of 20 pM 320 
(20 amoles) and 5 pM (25 amoles) was achieved. Thus, both methods are suitable for the 321 
analysis of P-III-NP at basal serum concentrations (5 ng/mL, 125 pM). Chromatographic data 322 
generated from trypsin digested immuno-captured human serum P-III-NP show peaks 323 
corresponding to the expected PTM hT1 and T5 peptides. These results support the 324 
conservation of PTMs across bovine and human species, strengthening the use of our selected 325 
peptides (hT1 and T5) for the development of quantitative LC/MS methods targeting P-III-326 
NP. Using our synthesised T5 peptide, we have semi-quantitatively estimated the basal 327 
concentration of hP-III-NP to be 50 pM (2 ng/mL) that are similar to concentrations 328 
estimated by immunoassay (Orion). To associate traceability to our methods, however, 329 
suitable reference material for the suggested peptides or intact P-III-NP is necessary. 330 
Figure 3: Extracted ion chromatogram of P-III-NP peptides, hT1 (precursor m/z 1038 and 331 
692) and T5 (precursor m/z 534), from a pooled human serum sample after trypsin digestion 332 
analysed by a) nano-flow LC/MS and b) micro-flow LC/MS. Peak intensity in relative 333 
abundance (%) and time (min) are shown on the y- and x-axes, respectively. The peak height 334 
(in absolute counts) and signal to noise ratio for each peak are annotated.  335 
Conclusions 336 
As a step towards developing a quantitative method based on mass spectrometry for 337 
analysing P-III-NP, the amino acid sequence of the protein has been partially sequenced. This 338 
has enabled the synthesis of appropriate peptides for the semi-quantitative LC/MS analysis of 339 
hP-III-NP in human serum. 340 
P-III-NP peptides, T1 and T5, have been identified for the first time through the analysis of a 341 
trypsin digested bP-III-NP sample by LC/MS/HRAMS. Based on the structure of P-III-NP, 342 
PTMs can be predicted. However, protein algorithms do not include these events when in 343 
silico-digests are conducted. Our study highlights the importance of including PTMs for 344 
protein MS identification, as sole dependence on generated in silico-digest fragments can 345 
lead to the misidentification of peptide fragments. Characterisation and identification of 346 
human P-III-NP peptides hT1 and T5 brings us one step closer towards developing a MS 347 
quantification method for determining P-III-NP concentrations, in blood that will be 348 
adaptable to anti-doping and clinical testing and will complement current immunoassays. 349 
However, to develop commutable quantitative methods for these fields, standardised 350 
international reference for P-III-NP (as peptides or intact protein, the latter being preferred) 351 
as well as heavy labelled “internal standards” are needed. 352 
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 420 
P-III-NP 
Precursor 
Peptide 
Precursor ion 
(m/z) 
Product ion 
(m/z) 
Collision 
energy 
(eV) 
hT1 
692 [M+3H]3+ 768 (b8)  10 
1038 [M+2H]2+ 240 (b2) 50 
1038 [M+2H]2+ 440 (b4) 40 
T5 
534 [M+2H]2+ 363 (y7
2+) 20 
534 [M+2H]2+ 448 (y9
2+) 13 
534 [M+2H]2+ 628 (y6) 27 
Table 1: Collision energies for SRM (selected reaction monitoring) transitions acquired for 421 
P-III-NP peptides by micro- and nano-ESI MS.  422 
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Peptide 
Reference 
Site of 
peptide in 
P-III-NP 
(aa) 
Peptide sequence Peptide 
length 
(aa) 
Molar 
Mass 
(Da) 
hT1 1-19 QQEAVEGGCSHLGQSYADR 19 2034.893 
bT1 1-19 QQEAVDGGCSHLGQSYADR 19 2019.870 
T2-4 20-85 
DVWKPEPCQICVCDSGSVLCDDII
CDDQELDCPNPEIPFGECCAVCPQ
PPTAPTRPPNGQGPQGPK 66 7020.075 
T5 86-96 GDPGPPGIPGR 11 1019.527 
hT6 97-130 
NGDPGIPGQPGSPGSPGPPGICESC
PTGPQNYSP 34 3218.415 
bT6 97-130 
NGDPGPPGSPGSPGSPGPPGICESC
PTGGQNYSP 34 3120.319 
Table 2: Unique trypsin in silico-derived digestion products for human (UniProt accession 423 
no. P02461(24-153)) and bovine (UniProt accession no. Q08E14 (24-153)) P-III-NP with no 424 
missed cleavages allowed. Where the amino acid sequence of peptides differ between species 425 
(residues highlighted in bold), h and b, represent human and bovine respectively. 426 
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Peptide Amino acid sequence Peptide ion (m/z) 
[M+H]
+
 [M+2H]
2+
 [M+3H]
3+
 
In silico T1 QQEAVDGGCSHLGQSYADR 2020.8777 1010.9425 674.2974 
Observed 
carbamidomethylated PTM 
T1 
pEQEAVDGGCSHLGQSYADR 
2060.8727 1030.9400 687.6291 
In silico T5 GDPGPPGIPGR 1019.5269 510.2671 340.5138 
Observed PTM T5 GD(hP)GP(hP)GI(hP)GR 1067.5116 534.2594 356.5087 
In silico T6 
NGDPGPPGSPGSPGSPGPPGIC
ESCPTGGQNYSP 3121.3262 1561.1667 1041.1136 
Table 3: Bovine P-III-NP trypsin digestion products selected for MS analysis, peptides shown 427 
are the theoretically derived in silico (Protein Cutter [19] and Protein Prospector [20]) and those 428 
observed with a PTM form within the experimental digest product. Pyroglutamate and 429 
hydroxylated proline residues are represented by pE and hP, respectively. Singly- ([M+H]+), 430 
doubly- ([M+2H]2+) and triply- ([M+3H]3+) charged ions for each peptide are presented. 431 
 432 
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Figure 1: Extracted ion chromatogram at m/z 1030.9400 ±5 ppm and corresponding product ion scan 
spectrum of the carbamidomethylated PTM bT1 triply-charged peptide (±1 u) using a normalised collision 
energy of 30 %. The most abundant b- and y-ions are annotated, where no charge is indicated the peptide 
is singly-charged.  
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Figure 2: Extracted ion chromatogram at m/z 534.2594 ±5 ppm and corresponding product ion scan 
spectrum of the fragmented PTM T5 doubly-charged peptide (±1 u) using a normalised collision energy of 
20 %. The most abundant b- and y-ions are annotated, where no charge is indicated the peptide is singly-
charged.  
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Figure 3: Extracted ion chromatogram of P-III-NP peptides, hT1 (precursor m/z 1038 and 692) and T5 
(precursor m/z 534), from a pooled human serum sample after trypsin digestion analysed by a) nano-flow 
LC/MS and b) micro-flow LC/MS. Peak intensity in relative abundance (%) and time (min) are shown on the 
y- and x-axes, respectively. The peak height (in absolute counts) and signal to noise ratio for each peak are 
annotated.  
 
249x256mm (300 x 300 DPI)  
 
 
Page 18 of 17
http://mc.manuscriptcentral.com/rcm
Rapid Communications in Mass Spectrometry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
